KUDO BIOTECHNOLOGY
DEAD

Serial Number

98069328

Owner

KUDO BIOTECHNOLOGY, INC.

Attorney

Lori J. Shyavitz

Filing Date

Jul 3, 2023

Add to watchlist:

No watchlists yet
View on USPTO

KUDO BIOTECHNOLOGY Trademark

Serial Number: 98069328

KUDO BIOTECHNOLOGY is a trademark filed by KUDO BIOTECHNOLOGY, INC. on July 3, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

KUDO BIOTECHNOLOGY, INC.

117 KENDRICK STREET
NEEDHAM, MA 02494

Entity Type: 03

RVAC Medicines Pte. Ltd. (2 trademarks)

c/o RVAC Medicines (US), Inc.
Waltham, MA 02451

Entity Type: 99

Trademark Details

Filing Date

July 3, 2023

Registration Date

Not Registered

Published for Opposition

December 31, 2024

Goods & Services

Custom manufacturing of pharmaceuticals, biological preparations and drug conjugates; custom assembly of pharmaceuticals, biological preparations and drug conjugates; custom manufacturing of pharmaceuticals; custom production of pharmaceuticals; custom production of biological preparations; custom manufacturing of chemical reagents; custom manufacturing of pharmaceutical preparations; custom manufacturing of biomedical preparations; custom manufacture of drug conjugates

Pharmaceutical preparations for the treatment of cancer, infectious disease, metabolic disease, and central nervous system disease; chemico-pharmaceutical preparations for the treatment of cancer, infectious disease, metabolic disease, and central nervous system disease; drugs for medical purposes, namely, anticancer preparations; biological preparations for the treatment of cancer, infectious disease, metabolic disease, and central nervous system disease; chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of cancer, infectious disease, metabolic disease, and central nervous system disease; medicinal preparations for human purposes for the treatment of cancer, infectious disease, metabolic disease, and central nervous system disease; pharmaceutical preparations, substances and compositions for the prevention of cancer, infectious disease, metabolic disease, and central nervous system disease and conditions

Scientific and engineering research services relating to the manufacture of biotechnology and pharmaceutical products; development of products for others; pharmaceutical drug development services; research and development of new products; biochemical research and development; custom design and development of chemical reagents, pharmaceutical formulations, and biologics; research and development in the pharmaceutical, biomedicine and biotechnology fields; research and development of nucleic acid medicines; research and development of mRNA drug substance and drug products; biomedical research services; development of pharmaceutical preparations and medicines

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 29, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 29, 2025 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 25, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 31, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 31, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 25, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 22, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 22, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 22, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 22, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 22, 2024 CNEA
ASSIGNED TO EXAMINER
Oct 7, 2024 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 23, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 23, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 24, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 24, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 22, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 22, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 22, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 15, 2024 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 24, 2024 ASGN
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 3, 2023 NWOS
NEW APPLICATION ENTERED
Jul 6, 2023 NWAP